Blog - Vital Signs - Life Science Business Development & Finance

7 Ways Regulation A+ Is Better Than Traditional Venture Capital

With CRISPR in Humans On The Horizon, Will the Public Back Intellia?

First, there were wearables. Now, there are swallowables

A cancer startup just raised $175 million from a pharmaceutical giant, and it could be where the industry is headed

Can Sean Parker Hack Cancer?

Stemcentrx Sale to Return a Record $1.7 Billion for VC Firm Founders Fund

Drugmakers Place Big Bets on Cancer Medicines

Blue Cross Invests in Hygieia, Partners on Diabetes Management Pilot

Startup Investors Hit the Brakes

$220M Richer, Human Longevity